Kiora Pharmaceuticals, Inc. KPRX
Set alert
1.56 USD -0.20 -11.36%
At close · Oct 30
1.66 +0.10 +6.35%
After hours · Oct 30, 4:00 PM ET
1.55 Day range 1.83
1.56 52-week range 2.86
- YTD
- -20.81%
- 1 year
- -38.82%
- Open
- 1.78
- Prev close
- 1.76
- Mkt cap
- 6.90M
- Vol
- 100.69K
- Avg vol
- 22.91K
- EPS
- -2.46
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.55
- High
- 1.83
- Forward P/E
- -1.48
- Beta
- -0.29
- Short ratio
- 0.27
- Inst. own
- 48.34%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Mar 28, 2024
- 50-d avg
- 3.47
- 200-d avg
- 4.14
- 1y target
- 40.50
2Y chart
Events in this range
- Nov 8, 2024Earnings: -0.81; estimate -0.9; surprise 10%
- Nov 12, 2024Rating: HC Wainwright & Co. · Buy → Buy
Signals (90)
| Name | Date | Ago |
|---|---|---|
| RSI: Oversold | Oct 29, 2026 | 2 days ago |
| RSI: Oversold | Oct 23, 2026 | 1 week ago |
| MACD: Sell Signal | Sep 29, 2026 | 1 month ago |
| MACD: Buy Signal | Sep 14, 2026 | 1 month ago |
| SMA: Bullish | Sep 10, 2026 | 1 month ago |
| SMA: Bearish | Sep 3, 2026 | 1 month ago |
| SMA: Bullish | Sep 2, 2026 | 1 month ago |
| SMA: Bearish | Aug 31, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 31, 2026 | 2 months ago |
| SMA: Bullish | Aug 17, 2026 | 2 months ago |
| SMA: Bearish | Aug 14, 2026 | 2 months ago |
| SMA: Bullish | Aug 7, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 6, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 4, 2026 | 2 months ago |
| MACD: Buy Signal | Jul 28, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 23, 2026 | 3 months ago |
| SMA: Bearish | Jul 21, 2026 | 3 months ago |
| SMA: Bullish | Jul 17, 2026 | 3 months ago |
| MACD: Buy Signal | Jul 17, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 7, 2026 | 3 months ago |
| SMA: Bearish | Jul 6, 2026 | 3 months ago |
| MACD: Buy Signal | Jul 1, 2026 | 4 months ago |
| SMA: Bullish | Jun 23, 2026 | 4 months ago |
| SMA: Bearish | Jun 18, 2026 | 4 months ago |
| SMA: Bullish | Jun 16, 2026 | 4 months ago |
| SMA: Bearish | Jun 15, 2026 | 4 months ago |
| MACD: Sell Signal | Jun 4, 2026 | 4 months ago |
| MACD: Buy Signal | May 20, 2026 | 5 months ago |
| MACD: Sell Signal | May 18, 2026 | 5 months ago |
| MACD: Buy Signal | May 13, 2026 | 5 months ago |
| SMA: Bullish | May 1, 2026 | 6 months ago |
| SMA: Bearish | Apr 24, 2026 | 6 months ago |
| MACD: Sell Signal | Apr 24, 2026 | 6 months ago |
| SMA: Bullish | Apr 8, 2026 | 6 months ago |
| RSI: Overbought | Apr 8, 2026 | 6 months ago |
| SMA: Bullish | Apr 7, 2026 | 6 months ago |
| MACD: Buy Signal | Apr 7, 2026 | 6 months ago |
| MACD: Sell Signal | Mar 23, 2026 | 7 months ago |
| SMA: Bearish | Mar 13, 2026 | 7 months ago |
| SMA: Bullish | Mar 9, 2026 | 7 months ago |
| MACD: Buy Signal | Mar 9, 2026 | 7 months ago |
| SMA: Bearish | Feb 12, 2026 | 8 months ago |
| MACD: Sell Signal | Feb 5, 2026 | 8 months ago |
| MACD: Buy Signal | Jan 29, 2026 | 9 months ago |
| MACD: Sell Signal | Jan 26, 2026 | 9 months ago |
| SMA: Bullish | Jan 7, 2026 | 9 months ago |
| MACD: Buy Signal | Jan 5, 2026 | 9 months ago |
| MACD: Sell Signal | Dec 29, 2025 | 10 months ago |
| MACD: Buy Signal | Dec 2, 2025 | 11 months ago |
| RSI: Oversold | Nov 19, 2025 | 11 months ago |
| RSI: Oversold | Oct 22, 2025 | 1 year ago |
| SMA: Bearish | Oct 20, 2025 | 1 year ago |
| MACD: Sell Signal | Oct 16, 2025 | 1 year ago |
| SMA: Bullish | Sep 30, 2025 | 1 year ago |
| MACD: Buy Signal | Sep 30, 2025 | 1 year ago |
| MACD: Sell Signal | Sep 12, 2025 | 1 year ago |
| SMA: Bearish | Aug 28, 2025 | 1 year ago |
| SMA: Bearish | Aug 18, 2025 | 1 year ago |
| SMA: Bullish | Aug 15, 2025 | 1 year ago |
| MACD: Buy Signal | Aug 15, 2025 | 1 year ago |
| RSI: Oversold | Aug 5, 2025 | 1 year ago |
| MACD: Sell Signal | Jul 28, 2025 | 1 year ago |
| SMA: Bearish | Jul 24, 2025 | 1 year ago |
| SMA: Bullish | Jul 23, 2025 | 1 year ago |
| SMA: Bearish | Jul 22, 2025 | 1 year ago |
| SMA: Bullish | Jul 16, 2025 | 1 year ago |
| MACD: Buy Signal | Jul 10, 2025 | 1 year ago |
| SMA: Bearish | Jun 24, 2025 | 1 year ago |
| SMA: Bullish | Jun 20, 2025 | 1 year ago |
| SMA: Bearish | Jun 13, 2025 | 1 year ago |
| MACD: Sell Signal | Jun 12, 2025 | 1 year ago |
| SMA: Bullish | Jun 3, 2025 | 1 year ago |
| MACD: Buy Signal | Jun 3, 2025 | 1 year ago |
| RSI: Overbought | Jun 3, 2025 | 1 year ago |
| SMA: Bearish | May 27, 2025 | 1 year ago |
| MACD: Sell Signal | May 14, 2025 | 1 year ago |
| SMA: Bullish | Apr 23, 2025 | 1 year ago |
| MACD: Buy Signal | Apr 15, 2025 | 1 year ago |
| RSI: Oversold | Apr 10, 2025 | 1 year ago |
| RSI: Oversold | Apr 4, 2025 | 1 year ago |
| MACD: Sell Signal | Mar 26, 2025 | 1 year ago |
| MACD: Buy Signal | Mar 13, 2025 | 1 year ago |
| SMA: Bearish | Feb 19, 2025 | 1 year ago |
| SMA: Bullish | Feb 13, 2025 | 1 year ago |
| SMA: Bearish | Feb 11, 2025 | 1 year ago |
| MACD: Sell Signal | Feb 5, 2025 | 1 year ago |
| MACD: Buy Signal | Jan 17, 2025 | 1 year ago |
| SMA: Bullish | Jan 16, 2025 | 1 year ago |
| MACD: Sell Signal | Jan 14, 2025 | 1 year ago |
| MACD: Buy Signal | Jan 2, 2025 | 1 year ago |
Key statistics
- Market cap
- 9.87M
- Enterprise value
- -17.14M
- Trailing P/E
- 3.13
- Forward P/E
- -1.48
- PEG ratio
- 0.00
- Price / sales
- 0.62
- Price / book
- 0.46
- EPS (TTM)
- 1.05
- Beta
- -0.29
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 19.98%
- Revenue (TTM)
- 16.02M
- Revenue growth
- 0.00%
- Free cash flow
- 1.47M
- Total cash
- 27.82M
- Total debt
- 82.32K
- Return on equity
- 13.69%
- Shares outstanding
- 3.00M
- Short % of float
- 0.12%
- 50-day average
- 3.47
- 200-day average
- 4.14
Analyst view
Consensus: none
Price target (mean) 40.50 +2496.2% upside
Now 1.56
- Target (low)
- 27.00
- Target (mean)
- 40.50
- Target (high)
- 54.00
Ratings (0m) 3 3 buy · 0 hold · 0 sell
- Strong buy2
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Mar 28, 2024
Expected Mar 28, 2024. Consensus EPS estimate -0.70.
Financials — quick view
KPRX Revenue — quarterly 0
KPRX Net income — quarterly -2.08M
KPRX EPS — quarterly -0.34
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 8, 2024 | Sep 1, 2024 | -0.90 | -0.81 | +0.09 | +10.00% |
| Aug 9, 2024 | Jun 1, 2024 | -0.95 | -0.53 | +0.42 | +44.21% |
| May 10, 2024 | Mar 1, 2024 | 5.58 | 3.42 | -2.16 | -38.71% |
| Mar 28, 2024 | Dec 1, 2023 | -0.33 | — | — | — |
| Nov 9, 2023 | Sep 1, 2023 | -2.70 | -8.01 | -5.31 | -196.67% |
| Aug 8, 2023 | Jun 1, 2023 | -4.59 | -7.11 | -2.52 | -54.90% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 12, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 22, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Jul 23, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| May 20, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Mar 27, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Feb 9, 2024 | HC Wainwright & Co. | main | Buy | Buy |
About Kiora Pharmaceuticals, Inc.
Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 2 clinical trials indicated for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. The company is also developing KIO-104, a non-steroidal, immuno-modulatory, small-molecule inhibitor of dihydroorotate dehydrogenase, currently under phase 1b/2a study for the treatment of posterior non-infectious uveitis, as well as under pre-clinical development for the treatment of proliferative vitreoretinopathy; KIO-101, an eye drop for the treatment of ocular presentation of rheumatoid arthritis; and KIO-201, an eye drop for treating patients undergoing photorefractive keratectomy (PRK) surgery for corneal wound repair. It has commercialization agreement with 4SC Discovery GmbH, for KIO-101; and collaboration agreement with Théa Open Innovation for the development KIO-301. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Encinitas, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- kiorapharma.com
News
- 12 Health Care Stocks Moving In Thursday's Intraday Session
- Kiora Pharmaceuticals Obtains Exclusive Development And Commercialization Rights, Outside Asia, To KIO-401 From Senju Pharmaceutical For Central Retinal Artery Occlusion For $3.5M In Upfront Payment And $285M In Additional Milestones And Royalties-8K Filing
- Kiora Pharmaceuticals Licenses South Korean Ophthalmic Development and Commercialization Rights for KIO-301 to Chong Kun Dang Pharmaceutical Corporation
- Kiora Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update
- Kiora Pharmaceuticals to Participate in Piper Sandler Virtual Ophthalmology Symposium
- Kiora Pharmaceuticals Reports its Ion Channel Modulator, KIO-300, Suppressed Seizure Activity in Preclinical Epilepsy Model
- Kiora Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update
- Kiora's Phase 1 ABACUS Study of KIO-301 in Retinitis Pigmentosa Published in Nature Medicine; Phase 2 Trial Underway
- Financial Comparison: Cronos Group (NASDAQ:CRON) & Kiora Pharmaceuticals (NASDAQ:KPRX)
- 12 Health Care Stocks Moving In Monday's After-Market Session
Your note
Sign in to keep a note on KPRX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| DANIELS ERIC JOSEPH | Officer | Stock Award(Grant) | Jun 30, 2024 | 18,577 |
| PARSONS ERIN | Director | Purchase | Jun 12, 2024 | 0 |
| SHAPIRO ARON | Director | Purchase | Sep 9, 2024 | 0 |
| STENGONE CARMINE N | Director | Purchase | Sep 10, 2024 | 1,250 |
| STREM BRIAN M. | Chief Executive Officer | Stock Award(Grant) | Jun 30, 2024 | 30,160 |
| TOSCA MELISSA | Chief Financial Officer | Purchase | Aug 13, 2024 | 13,599 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Rosalind Advisors, Inc. | 8.52% | 255,555 | 840.77K | Sep 29, 2024 |
| AIGH Capital Management LLC | 8.52% | 255,555 | 840.77K | Sep 29, 2024 |
| Nantahala Capital Management, LLC | 7.04% | 211,110 | 694.55K | Sep 29, 2024 |
| Stonepine Capital Management, LLC | 6.74% | 202,400 | 665.89K | Sep 29, 2024 |
| Adar1 Capital Management, LLC | 6.55% | 196,551 | 646.65K | Sep 29, 2024 |
| Alyeska Investment Group, L.p. | 6.02% | 180,780 | 594.77K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 0.45% | 13,435 | 44.20K | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.09% | 2,729 | 8.98K | Sep 29, 2024 |
| Bridgeway Fds Inc-Omni Small Cap Value Fund | 0.07% | 2,000 | 6.58K | Sep 29, 2024 |
| Fidelity Series Total Market Index Fund | 0.05% | 1,413 | 4.65K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.02% | 747 | 2.46K | Oct 30, 2024 |